Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001

Cancer Immunology, Immunotherapy

Volumn 61, Issue 2, 2012, Pages 157-168

  Vetsika, Eleni Kyriaki ^a   Konsolakis, Georgios ^a   Aggouraki, Despoina ^a   Kotsakis, Athanasios ^b   Papadimitraki, Elisavet ^b   Christou, Soultana ^b   Menez Jamet, Jeanne ^c   Kosmatopoulos, Kostas ^c   Georgoulias, Vassilis ^a,b,d   Mavroudis, Dimitris ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c Vaxon Biotech   (France)

^d KAT HOSPITAL   (Greece)

Author keywords

CD8+ T cells; Cryptic peptide; Immunotherapy; Telomerase; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; PEPTIDE VACCINE; PERFORIN; TELOMERASE; UNCLASSIFIED DRUG; VX 001;

ADULT; ADVANCED CANCER; AGED; BILE DUCT CANCER; BREAST CANCER; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PATIENT; CANCER STAGING; CELLULAR IMMUNITY; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; KIDNEY CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; T LYMPHOCYTE; TUMOR IMMUNITY;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TELOMERASE; VACCINATION;

EID: 84856709105     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1093-4     Document Type: Review

References (38)

1. D Nagorsen C Scheibenbogen FM Marincola A Letsch U Keilholz 2003 Natural T cell immunity against cancer Clin Cancer Res 9 4296 4303 14555498 1:CAS:528:DC%2BD3sXotVShsLw%3D (Pubitemid 37248383)
2. MJ Smyth GP Dunn RD Schreiber 2006 Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity Adv Immunol 90 1 50 16730260 10.1016/S0065-2776(06) 90001-7 1:CAS:528:DC%2BD1cXhsVCjtbc%3D (Pubitemid 43765795)
3. P van der Bruggen Y Zhang P Chaux, et al. 2002 Tumor-specific shared antigenic peptides recognized by human T cells Immunol Rev 188 51 64 10.1034/j.1600-065X.2002.18806.x (Pubitemid 35398865)
4. MA Blasco 2005 Telomeres and human disease: ageing, cancer and beyond Nat Rev Genet 6 611 622 16136653 10.1038/nrg1656 1:CAS:528:DC%2BD2MXntFeqtbw%3D (Pubitemid 41044298)
5. NW Kim MA Piatyszek KR Prowse, et al. 1994 Specific association of human telomerase activity with immortal cells and cancer Science 266 2011 2015 7605428 10.1126/science.7605428 1:CAS:528:DyaK2MXisl2lu7g%3D
6. WC Hahn CM Counter AS Lundberg RL Beijersbergen MW Brooks RA Weinberg 1999 Creation of human tumour cells with defined genetic elements Nature 400 464 468 10440377 10.1038/22780 1:CAS:528:DyaK1MXltVGmtLc%3D (Pubitemid 29361801)
7. WC Hahn SA Stewart MW Brooks, et al. 1999 Inhibition of telomerase limits the growth of human cancer cells Nat Med 5 1164 1170 10502820 10.1038/13495 1:CAS:528:DyaK1MXms1Wktrk%3D (Pubitemid 29474421)
8. PF Robbins Y Kawakami 1996 Human tumor antigens recognized by T cells Curr Opin Immunol 8 628 636 8902387 10.1016/S0952-7915(96)80078-1 1:CAS:528:DyaK28Xmt1Ogtrw%3D (Pubitemid 26385390)
9. PA Van BP van der PG Coulie, et al. 1995 Genes coding for tumor antigens recognized by cytolytic T lymphocytes Immunol Rev 145 229 250 10.1111/j.1600-065X.1995.tb00084.x
10. S Tourdot A Scardino E Saloustrou, et al. 2000 A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes Eur J Immunol 30 3411 3421 11093159 10.1002/1521-4141(2000012)30:12<3411::AID-IMMU3411>3.0. CO;2-R 1:CAS:528:DC%2BD3MXpt1Kk (Pubitemid 32005212)
11. DA Gross S Graff-Dubois P Opolon, et al. 2004 High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy J Clin Invest 113 425 433 14755339 1:CAS:528:DC%2BD2cXhtFSls7g%3D (Pubitemid 38544186)
12. A Scardino DA Gross P Alves, et al. 2002 HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy J Immunol 168 5900 5906 12023395 1:CAS:528:DC%2BD38XktFCrtLY%3D (Pubitemid 34556179)
13. J Hernandez F Garcia-Pons YC Lone, et al. 2002 Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells Proc Natl Acad Sci USA 99 12275 12280 12218171 10.1073/pnas.182418399 1:CAS:528: DC%2BD38XntlCks7Y%3D
14. D Mavroudis I Bolonakis S Cornet, et al. 2006 A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies Oncology 70 306 314 17047402 10.1159/000096252 1:CAS:528:DC%2BD28XhtFGjs7vO (Pubitemid 44670173)
15. I Bolonaki A Kotsakis E Papadimitraki, et al. 2007 Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide J Clin Oncol 25 2727 2734 17602077 10.1200/JCO.2006.10.3465 1:CAS:528:DC%2BD2sXosValtLo%3D (Pubitemid 47123180)
16. SL Meijer A Dols SM Jensen, et al. 2007 Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2 M peptide J Immunother 30 533 543 17589294 10.1097/CJI. 0b013e3180335b5e 1:CAS:528:DC%2BD2sXmslygu7g%3D (Pubitemid 46988087)
17. SA Rosenberg JC Yang DJ Schwartzentruber, et al. 1998 Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 321 327 9500606 10.1038/nm0398-321 1:CAS:528:DyaK1cXhs1Kju7c%3D (Pubitemid 28144091)
18. MR Parkhurst ML Salgaller S Southwood, et al. 1996 Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues J Immunol 157 2539 2548 8805655 1:CAS:528:DyaK28Xls1aitr4%3D (Pubitemid 126450467)
19. D Valmori JF Fonteneau CM Lizana, et al. 1998 Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues J Immunol 160 1750 1758 9469433 1:CAS:528:DyaK1cXhtVyksLY%3D (Pubitemid 28110836)
20. N Bercovici N Haicheur S Massicard, et al. 2008 Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients J Immunother 31 101 112 18157017 10.1097/CJI.0b013e318159f5ba (Pubitemid 351619409)
21. B Zuber V Levitsky G Jonsson, et al. 2005 Detection of human perforin by ELISpot and ELISA: ex vivo identification of virus-specific cells J Immunol Methods 302 13 25 16005014 10.1016/j.jim.2005.04.015 1:CAS:528: DC%2BD2MXntVGmsLY%3D (Pubitemid 41111869)
22. IJM De Vries WJ Lesterhuis JO Barentsz, et al. 2005 Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy Nat Biotechnol 23 1407 1413 16258544 10.1038/nbt1154 (Pubitemid 41679393)
23. CL Slingluff Jr GR Petroni GV Yamshchikov, et al. 2004 Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule J Clin Oncol 22 4474 4485 15542798 10.1200/JCO.2004.10.212 1:CAS:528:DC%2BD2cXhtFWqt77F (Pubitemid 41185113)
24. TZ Zaks DB Chappell SA Rosenberg NP Restifo 1999 Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition J Immunol 162 3273 3279 10092779 1:CAS:528: DyaK1MXhvV2rtLc%3D (Pubitemid 29313574)
25. A Aruga E Aruga K Tanigawa DK Bishop VK Sondak AE Chang 1997 Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role J Immunol 159 664 673 9218581 1:CAS:528:DyaK2sXksVyms70%3D (Pubitemid 127484215)
26. EC Lattime MJ Mastrangelo O Bagasra W Li D Berd 1995 Expression of cytokine mRNA in human melanoma tissues Cancer Immunol Immunother 41 151 156 7553683 10.1007/BF01521340 1:CAS:528:DyaK2MXpslWisLY%3D
27. AS Yang EC Lattime 2003 Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses Cancer Res 63 2150 2157 12727833 1:CAS:528:DC%2BD3sXjtlGmtro%3D (Pubitemid 36538620)
28. EM Gabriel EC Lattime 2007 Anti-CTL-associated antigen 4: are regulatory T cells a target? Clin Cancer Res 13 785 788 17289867 10.1158/1078-0432.CCR-06- 2820 (Pubitemid 46340349)
29. FS Hodi MC Mihm RJ Soiffer, et al. 2003 Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci USA 100 4712 4717 12682289 10.1073/pnas.0830997100 1:CAS:528:DC%2BD3sXjt12nsL4%3D (Pubitemid 36457795)
30. A Korman M Yellin T Keler 2005 Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies Curr Opin Investig Drugs 6 582 591 15988909 1:CAS:528:DC%2BD2MXlvFOntL0%3D (Pubitemid 40852291)
31. MF Krummel JP Allison 1995 CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation J Exp Med 182 459 465 7543139 10.1084/jem.182.2.459 1:CAS:528:DyaK2MXntFKhsL4%3D
32. GQ Phan JC Yang RM Sherry, et al. 2003 Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sci USA 100 8372 8377 12826605 10.1073/pnas.1533209100 1:CAS:528:DC%2BD3sXlsFGnt7c%3D (Pubitemid 36842552)
33. J Sun J Schiffman A Raghunath TD Ng H Chen P Sharma 2008 Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy Cancer Immun 8 9 18503261
34. KL Ling SE Pratap GJ Bates, et al. 2007 Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients Cancer Immun 7 7 17388261
35. D O'Mahony JC Morris C Quinn, et al. 2007 A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clin Cancer Res 13 958 964 17289891 10.1158/1078-0432.CCR-06-1974 (Pubitemid 46340373)
36. S Sakaguchi 2000 Regulatory T cells: key controllers of immunologic self-tolerance Cell 101 455 458 10850488 10.1016/S0092-8674(00)80856-9 1:CAS:528:DC%2BD3cXjvFWntL4%3D
37. S Sakaguchi 2005 Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self Nat Immunol 6 345 352 15785760 10.1038/ni1178 1:CAS:528:DC%2BD2MXisVyitLY%3D (Pubitemid 41716771)
38. T Yamaguchi S Sakaguchi 2006 Regulatory T cells in immune surveillance and treatment of cancer Semin Cancer Biol 16 115 123 16376102 10.1016/j.semcancer.2005.11.005 1:CAS:528:DC%2BD28XhtVGisrk%3D (Pubitemid 43172060)